Form 4: Precigen CLO Donald Lehr Receives Equity Grant
Statement of Changes in Beneficial Ownership
Precigen Chief Legal Officer Donald P. Lehr was granted 358,000 stock options and 107,000 restricted stock units.
Summary
- Donald P. Lehr, Chief Legal Officer of Precigen, Inc., received a new equity compensation package on April 20, 2026.
- The grant consists of 358,000 stock options with an exercise price of $4.11 per share.
- The grant also includes 107,000 restricted stock units (RSUs), each representing a right to one share of common stock.
- Both the options and RSUs follow a four-year vesting schedule beginning May 23, 2027.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that carries no significant signal regarding company performance.
Positives
- Equity grants align the interests of the Chief Legal Officer with long-term shareholder value.
- The multi-year vesting schedule encourages executive retention.
Negatives
- The issuance of new equity awards results in potential future dilution for existing shareholders.
Risks
- Future dilution of common stock upon the exercise of options and vesting of RSUs.
- Market price volatility affecting the value of the granted equity.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on executive compensation changes.
Industry Context
StockSavvy.ai notes that equity-based compensation remains the standard mechanism for incentivizing executive leadership in the biotechnology sector, particularly for companies focused on long-term R&D and clinical development.
Comparison to Industry Standards
- The four-year vesting schedule is consistent with standard corporate governance practices for executive equity grants in the U.S. biotech industry.
- The use of both options and RSUs is a common hybrid compensation strategy used by mid-cap firms to balance performance incentives and retention.
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise or vesting of these equity instruments.
Next Steps
- Vesting of 25% of the options and RSUs on May 23, 2027.
Key Dates
| Date | Description |
|---|---|
| 04/20/2026 | Date of the equity grant transaction. |
| 04/22/2026 | Date the Form 4 was signed and filed. |
| 05/23/2027 | Initial vesting date for both options and RSUs. |
| 04/20/2036 | Expiration date for the stock options. |
Keywords
Precigen, PGEN, Form 4, Insider Trading, Equity Compensation, Stock Options, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.